The DOI matches its Crossref record; the references it cites are not checked yet.
Early childhood height, weight, and BMI development in children with monogenic obesity: a European multicentre, retrospective, observational study
Open accessAbstract
Background Monogenic defects in the leptin-melanocortin pathway are associated with hyperphagia and severe, early-onset obesity. Early childhood growth patterns in height, weight, and BMI, might serve as phenotypic markers for specific genetic disorders; however, reliable data are scarce. This study aimed to evaluate the natural history of height, weight, and BMI in early childhood in a large European group of individuals with monogenic obesity. Methods This multicentre observational study analysed height, weight, and BMI from birth to age 5 years in individuals diagnosed with biallelic (likely) pathogenic LEP, LEPR, POMC, PCSK1, or MC4R variants or monoallelic (likely) pathogenic MC4R variants from six European centres (Berlin and Ulm, Germany; Cambridge, UK; Madrid, Spain; Paris, France; Rotterdam, Netherlands). All patient data up to May 31, 2022 were included in this analysis. All individuals had at least two height or weight measurements between birth and age 5 years. Early childhood growth trajectories were compared with those of control children with obesity without a known genetic cause, following a negative next-generation sequencing panel. Diagnostic performance of BMI as a predictor test for monogenic obesity was also evaluated. Findings We included 147 individuals with monogenic obesity. From the age of 6 months onwards, children with biallelic variants (n=88, 55% female vs 45% male) had substantially higher BMIs than those with monoallelic MC4R variants (n=59, 53% female vs 47% male) and control children (n=113, 59% female vs 41% male). Children with biallelic LEP, LEPR , and MC4R variants showed a steep BMI increase during the first year of life, followed by a plateau until age 5 years, whereas those with biallelic POMC variants did not plateau. Accelerated linear growth was only observed in children with biallelic MC4R variants starting from age 1 year. The optimal BMI cut-off for distinguishing individuals with biallelic variants from control individuals was identified at age 2 years, with a test positivity cutoff of 24·0 kg/m 2 (sensitivity: 0·96 [95% CI 0·89–1·00], specificity: 0·83 [0·74–0·90], AUC: 0·96 [0·91–0·99], p<0·0001). However, BMI had poor diagnostic performance for monoallelic MC4R variants. Interpretation This study identified characteristic early childhood BMI trajectories for different forms of monogenic obesity. From age 6 months onwards, individuals with biallelic variants can be distinguished from those with monoallelic variants and common obesity. A BMI ≥24 kg/m 2 at age 2 years had good diagnostic performance for biallelic variants, informing future recommendations for genetic screening for monogenic obesity. Funding Federal Ministry of Education and Research as part of the German Center for Child and Adolescent Health, German Research Foundation, Spanish Ministry of Health, The Wellcome Trust, Botnar Fondation, Leducq Foundation, National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, and NIHR Senior Investigator Award.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Setmelanotide is approved by the FDA and EMA for treatment of obesity and control of hunger in children above age 2 with Bardet-Biedl syndrome or biallelic POMC, PCSK1, or LEPR deficiency.
“Setmelanotide, a selective agonist of the MC4R, is approved by the FDA and EMA for the treatment of obesity and control of hunger in Bardet-Biedl Syndrome or biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency in affected children above age 2 years-old [103].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [103]
Obesity beginning before age 2 with a rapid increase in BMI (>2 SD above mean) during the first year followed by plateau or continued steady rise should prompt further medical evaluation for monogenic obesity.
“Obesity that begins before the age of 2, characterized by a rapid increase in BMI (> 2 standard deviations above the mean) during the first year of life followed by either a plateau or a continued steady rise, should prompt further medical evaluation for monogenic obesity [103].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [103]
Citations
The citation lists haven’t been fetched yet
References 31 · Cited by 19
Research works printed but not linked: 27
- Loos, 2022, The genetics of obesity: from discovery to biology, Nat Rev Genet, 23, 120, 10.1038/s41576-021-00414-z · DOI · Paper page
- Courbage, 2021, Implication of heterozygous variants in genes of the leptin-melanocortin pathway in severe obesity, J Clin Endocrinol Metab, 106, 2991, 10.1210/clinem/dgab404 · DOI
- Kleinendorst, 2020, Leptin receptor deficiency: a systematic literature review and prevalence estimation based on population genetics, Eur J Endocrinol, 182, 47, 10.1530/EJE-19-0678 · DOI
- Kleinendorst, 2018, Genetic obesity: next-generation sequencing results of 1230 patients with obesity, J Med Genet, 55, 578, 10.1136/jmedgenet-2018-105315 · DOI
- Wade, 2021, Loss-of-function mutations in the melanocortin 4 receptor in a UK birth cohort, Nat Med, 27, 1088, 10.1038/s41591-021-01349-y · DOI · Paper page
- Farooqi, 2003, Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene, N Engl J Med, 348, 1085, 10.1056/NEJMoa022050 · DOI · Paper page
- Farooqi, 1999, Effects of recombinant leptin therapy in a child with congenital leptin deficiency, N Engl J Med, 341, 879, 10.1056/NEJM199909163411204 · DOI · Paper page
- Hampl, 2023, Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity, Pediatrics, 151
- Styne, 2017, Pediatric obesity-assessment, treatment, and prevention: an endocrine society clinical practice guideline, J Clin Endocrinol Metab, 102, 709, 10.1210/jc.2016-2573 · DOI
- Abawi, 2023, Genetic obesity disorders: body mass index trajectories and age of onset of obesity compared with children with obesity from the general population, J Pediatr, 262, 10.1016/j.jpeds.2023.113619 · DOI
- Kohlsdorf, 2018, Early childhood BMI trajectories in monogenic obesity due to leptin, leptin receptor, and melanocortin 4 receptor deficiency, Int J Obesity (2005), 42, 1602, 10.1038/s41366-018-0049-6 · DOI
- Wabitsch, 2022, Natural history of obesity due to POMC, PCSK1, and LEPR deficiency and the impact of setmelanotide, J Endocr Soc, 6, 10.1210/jendso/bvac057 · DOI
- Cheng, 2023, Accurate proteome-wide missense variant effect prediction with AlphaMissense, Science, 381, 10.1126/science.adg7492 · DOI · Paper page
- de Onis, 2007, Development of a WHO growth reference for school-aged children and adolescents, Bull World Health Organ, 85, 660, 10.2471/BLT.07.043497 · DOI · Paper page
- Kempf, 2021, Dynamic alterations in linear growth and endocrine parameters in children with obesity and height reference values, EClinicalMedicine, 37, 10.1016/j.eclinm.2021.100977 · DOI
- Tanner, 1970, Standards for children's height at ages 2–9 years allowing for heights of parents, Arch Dis Child, 45, 755, 10.1136/adc.45.244.755 · DOI
- Cole, 1990, The LMS method for constructing normalized growth standards, Eur J Clin Nutr, 44, 45
- Cole, 1992, Smoothing reference centile curves: the LMS method and penalized likelihood, Stat Med, 11, 1305, 10.1002/sim.4780111005 · DOI
- Zorn, 2022, Measuring hyperphagia in patients with monogenic and syndromic obesity, Appetite, 178, 10.1016/j.appet.2022.106161 · DOI
- Krude, 2003, Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10, J Clin Endocrinol Metab, 88, 4633, 10.1210/jc.2003-030502 · DOI
- Gregoric, 2021, Two cases with an early presented proopiomelanocortin deficiency-a long-term follow-up and systematic literature review, Front Endocrinol (Lausanne), 12, 10.3389/fendo.2021.689387 · DOI
- von Schnurbein, 2024, Classification of congenital leptin deficiency, J Clin Endocrinol Metab, 109, 2602, 10.1210/clinem/dgae149 · DOI
- Putri, 2023, Height and growth velocity in children and adolescents undergoing obesity treatment: a prospective cohort study, J Clin Endocrinol Metab, 109, e314, 10.1210/clinem/dgad419 · DOI
- Ketelslegers, 1995, Nutritional regulation of insulin-like growth factor-I, Metabolism, 44, 50, 10.1016/0026-0495(95)90221-X · DOI
- Lam, 2021, MC3R links nutritional state to childhood growth and the timing of puberty, Nature, 599, 436, 10.1038/s41586-021-04088-9 · DOI
- Beghini, 2021, Serum IGF1 and linear growth in children with congenital leptin deficiency before and after leptin substitution, Int J Obes (Lond), 45, 1448, 10.1038/s41366-021-00809-2 · DOI
- Nielsen, 2022, Body mass index trajectories from childhood to adulthood and age at onset of overweight and obesity: the influence of parents' weight status, Am J Epidemiol, 191, 1877, 10.1093/aje/kwac124 · DOI
Metadata
- Authors
- Zorn, S., de Groot, C. J., Brandt-Heunemann, S., von Schnurbein, J., Abawi, O., Bounds, R., Ruck, L., Guijo, B., Martos-Moreno, G. Á., Nicaise, C., Courbage, S., Klehr-Martinelli, M., Siebert, R., Dubern, B., Poitou, C., Clément, K., Argente, J., Kühnen, P., Farooqi, I. S., Wabitsch, M., & van den Akker, E.
- Affiliations
- University Hospital Ulm (DE)
- Erasmus MC (NL)
- University of Cambridge (GB)
- Hospital Infantil Universitario Niño Jesús (ES)
- Sorbonne Université (FR)
- Universität Ulm (DE)
- Inserm (FR)
- Instituto de Salud Carlos III (ES)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Wabitsch, Martin
- ORCID
- Venue
- The Lancet Child & Adolescent Health
- Publisher
- Elsevier BV
- Published
- 2025-05
- Volume
- 9
- Issue
- 5
- Pages
- 297-305
- ISSN
- 2352-4642 (ISSN-L)
- OpenAlex
- W4409454043
- Cited by
- 19
- References
- 31
- Citations by year
- 2026: 13 · 2025: 6
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Update notices
- erratum (2025-06-01)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet Child & Adolescent Health (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- Biblos-e Archivo (Universidad Autónoma de Madrid) (submittedVersion, cc-by)
- Funders
- European Regional Development Fund
- Bundesministerium für Bildung und Forschung (01GL2407A)
- Gobierno de Espana Ministerio de Sanidad (FIS-PI19/00166)
- German Research Foundation (KU 2673/6\u20131, KU 2673/7\u20131)
- NIHR Cambridge Biomedical Research Centre
- Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición
- Federal Ministry of Education and Research Berlin Office
- Wellcome Trust
- Fondation Botnar
- Fondation Leducq
- Instituto de Salud Carlos III
- Universität Ulm
- National Institute for Health and Care Research
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- monogenic obesity, leptin-melanocortin pathway, early childhood growth, body mass index, hyperphagia
- MeSH terms
- Body Height, Body Weight, Child Development, Child, Preschool, Europe, Female, Humans, Infant, Infant, Newborn, Male, Retrospective Studies, Body Mass Index, Receptor, Melanocortin, Type 4, Pediatric Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review